An evaluation of six placebo-controlled scientific trials with one,134 complete members concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) were connected with a larger ordinary improvement within the Ashworth scale for spasticity in a number of sclerosis clients compared with placebo,